Navigation Links
Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
Date:12/1/2008

Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children's Hospital, Health Sciences Centre in Winnipeg

MONTREAL, Dec. 1 /PRNewswire/ -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first infant patient in its clinical program for hypophosphatasia was dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment.

"Our enzyme replacement therapy program for hypophosphatasia has progressed well," said Robert Heft, CEO of Enobia. "Based upon the excellent preclinical data we are hopeful that hypophosphatasia patients will benefit from treatment with ENB-0040. We're grateful for everyone involved in expediting the treatment of this patient."

Under two separate protocols, ENB-0040 will be evaluated in both adults and infants afflicted with hypophosphatasia at sites in Canada and the United States. In August, physicians at the University of Manitoba dosed the first adult patient as part of that cohort to evaluate the safety, tolerability and pharmacokinetics of ENB-0040.

Enobia Pharma is pleased to reproduce below today's announcement made by Children's Hospital, Health Sciences Centre Winnipeg regarding the dosing of the first infant patient in the early ENB-0040 studies.

    CHILD RECEIVING POTENTIALLY LIFE-SAVING TREATMENT AT HSC AS PART OF INTERNATIONAL DRUG TRIAL

    Infant Girl From Belfast Flown To Winnipeg

WINNIPEG - A 9-month-old baby girl from Belfast is receiving potentially life-saving experimental treatment at Children's Hospital, Health Sciences Centre Winnipeg as part of an international drug trial.

The child has a bone disorde
'/>"/>

SOURCE Enobia Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
2. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
3. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
6. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
9. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
10. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...JOHANNESBURG, November 25 ,iThemba ...ery announced today,that they have signed a collab..., services. , Pyxis,s world class computa... be coupled with iThemba,s service division to pro...projects identified through Pyxis,international c...
(Date:11/25/2009)...ewswire/ -- ChemoCentryx, Inc., announced today ... PROTECT-1 (the Prospective Randomized Oral Therap...-EN(TM) (CCX282-B) in patients with moderate-to-se...y with a favorable safety and tolerability profile...icacy in the reduction of disease severity as defi...
(Date:11/24/2009)...-- ,, WHAT: Rom Houbens, a Belgian man though...uto accident, was actually fully conscious and awa...Morning America segment. The DynaVox EyeMax was f...th Locked-in Syndrome and other conditions can unl...ca -- Tuesday, November 24 available online at ...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2DIA FDA PhRMA to Host Progression Free Survival Oncology Workshop 55448 1DIA FDA PhRMA to Host Progression Free Survival Oncology Workshop 55448 2DIA FDA PhRMA to Host Progression Free Survival Oncology Workshop 55448 3The Gaming Industry Stacks the Deck Against Smokefree Workplaces in Indiana 55444 1The Gaming Industry Stacks the Deck Against Smokefree Workplaces in Indiana 55444 2Movember Presents at LIVESTRONG 28R 29 Global Cancer Summit in Dublin Ireland in Support of Mens Health 55440 1Movember Presents at LIVESTRONG 28R 29 Global Cancer Summit in Dublin Ireland in Support of Mens Health 55440 2Movember Presents at LIVESTRONG 28R 29 Global Cancer Summit in Dublin Ireland in Support of Mens Health 55440 3
...ilotinib) Effective in 77% of Patients Resistant o...rly) Phase of Chronic,Myeloid Leukaemia (CML)(1), ...e Root Cause of CML,Whilst Providing an Acceptable...na Expands CML Portfolio for Novartis, Providing E...ients With Tasigna(R) and the CML,Gold-Standard, G...
...resent preliminary Phase II data for the adj... mechanically-ventilated patients,...ether with Nektar Therapeutics (Nasdaq: NKTR ), t...on their unique drug-device combination Amikacin,I...l meeting. Amikacin,Inhale, currently being studie...
Other Medicine Technology:Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 2Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 3Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 4Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 5Amikacin Inhale Shows Promising Results in Phase II Study 2Amikacin Inhale Shows Promising Results in Phase II Study 3Amikacin Inhale Shows Promising Results in Phase II Study 4Amikacin Inhale Shows Promising Results in Phase II Study 5Amikacin Inhale Shows Promising Results in Phase II Study 6Amikacin Inhale Shows Promising Results in Phase II Study 7
(Date:11/27/2009)...ecipes.com , theworld,s#1foodsite,receivedrecord-...ionvisitorsthedaybeforeThanksgiving,providingaclea...eyear.TheaverageThanksgivingmealin2009weighedinat2...ar,sfeast.AccordingtotheAllrecipessite, SweetPotat...pe,acontrastfromlastyear,spopular HomestyleTurkeyt...
(Date:11/27/2009)...ilingual coloring books designed for children ages...ty to educate - inform parents and children alike ...osuars to ABC,S and a host of other topics. , ...ber 27, 2009 -- Today’s children have enough...y hour of the day, but one of the oldest and simpl...
(Date:11/27/2009)...active anatomy education apps from Modality and Li...nces learning opportunities for iPhone and iPod to...November 27, 2009 -- Modality, Inc. and Lippinco...ters Kluwer Health, today announced the availabili...Store. Clemente’s Anatomy, Rohen’s Pho...
(Date:11/26/2009)...RNewswire/ -- The diabetes population in the Unite... and annual medical spending on the disease is pro...oday, according to a study published in the Decemb...ng Diabetes ® Program (NCDP), a program of No...om the University of Chicago. ,, According to t...
(Date:11/26/2009)...olybdate (TM) has been shown in studies to be effe...e caused by an overload of copper, and certain met...however, is known about how the drug works at the ...rn University researchers now has provided an inva... bound to copper-loaded metallochaperones. The dru...
Breaking Medicine News(10 mins):Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3
...e most disabling aspect of Tourette syndrome is th...another disorder. The most frequent co-occurring ...icit hyperactivity disorder (ADHD), though the cau... New research published in the April 13 edition of...
...il 15 Washington State Nurses Association,(WSNA),...more than 15,000 RNs,in Washington State, is a fou...(NFN) and is playing a leadership role as the new ...nization that provides,WSNA and other member state...
...Reduces 2009 Operating Expenses to Address Continu...st-Quarter 2009 Financial Results on Tuesday, May ...c. (Nasdaq: CYNO ), a leading developer and ma... March 31, 2009. , , Reflecting continued softnes...
...il 15 /PRNewswire/ - FormularyDecisions.com, an on...eing officially introduced at AMCP,s 21st Annual M...ng Committee of prominent healthcare decision make... economic models, and other content that may be us...
... RxSamplesNow.com is a New, Web-Based Phar...to all Prescribing U.S. Healthcare Professionals. ...ufacturers Together in an Online Community at www...rug Will Be Available in a Variety of Formats. , ...
... New York law firm to represent executive ...ord from Obama Administration on recognition of co... New York (Lexis Nexis) April 15, 2009 -- Taub...llenges, has been retained by Local 2222 of the Am...
Other Medicine News:Health News:Tourette syndrome misconceptions only one battle for patients 2Health News:Washington State Nurses Association Announces Formation of a New National Nurses Union 2Health News:Cynosure Announces Preliminary Financial Results for the First Quarter of 2009 2Health News:Cynosure Announces Preliminary Financial Results for the First Quarter of 2009 3Health News:Cynosure Announces Preliminary Financial Results for the First Quarter of 2009 4Health News:Innovative Decision Support Tool Introduced at AMCP Annual Meeting 2Health News:Online Sampling Service for Healthcare Prescribers and Drug Manufacturers Launched by RxSamplesNow.com 2Health News:Online Sampling Service for Healthcare Prescribers and Drug Manufacturers Launched by RxSamplesNow.com 3Health News:Taubman Kimelman & Soroka Retained by AFGE Local 2222 to Advise in Organizing of New York and New Jersey Transportation Security Officers 2
Liquichek Autoimmune Controls - ANA
Lyphochek Assayed Chemistry Control
Lyphochek Benzo/TCA Control Set A
Lyphochek Benzo/TCA Control Set B
Medicine Products: